Lantern Pharma Inc reports results for the quarter ended in March - Earnings Summary

Lantern Pharma

09/05/2023 23:01

* Lantern Pharma Inc  LTRN.OQ  reported a quarterly adjusted
loss
of 36 cents​​ per share for the quarter ended in March. The lone
analyst forecast for the quarter was for a loss of 48 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Lantern Pharma Inc's reported EPS for the quarter was a
loss
of 36 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Lantern Pharma Inc shares had risen by 9.7% this
quarter and
lost 12.3% so far this year.
    * The company reported a quarterly loss of $3.87 million.
    * Wall Street's median 12-month price target for Lantern
Pharma
Inc is $15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.48          -0.36          Beat
 Dec. 31 2022      -0.47          -0.31          Beat
 Sep. 30 2022      -0.48          -0.21          Beat
 Jun. 30 2022      -0.52          -0.41          Beat